BIOMAT Database Logo BIOMAT Database Logo

[Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders]. 1989

R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
First Department of Internal Medicine, School of Medicine, Nagoya University.

Infectious episodes in 90 patients with hematological disorders were treated with sulbactam/cefoperazone (SBT/CPZ), a new combination drug of a potent beta-lactamase inhibitor, sodium sulbactam, and a third generation cephalosporin, sodium cefoperazone. Clinical responses to the SBT/CPZ regimen were excellent in 23 cases, good in 30 cases, fair in 11 cases, and poor in 26 cases. The overall efficacy rate (percentage of cases showing excellent or good responses) was 58.9%. Efficacy rates classified according to different infections were: 80% in documented sepsis, 57.6% in suspected sepsis, 61.1% in pneumonia and 50% in other infections. One episode of side effect was encountered with redness and itching of skin. Hepatic disorders were observed in 3 cases. These adverse reactions, however, were not serious. These results indicate that SBT/CPZ has a high therapeutic efficacy to severe infections in patients with hematological disorders.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002438 Cefoperazone Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections. Cefobid,Cefoperazon,Cefoperazone Sodium,Cefoperazone Sodium Salt,Céfobis,T-1551,T1551,Salt, Cefoperazone Sodium,Sodium Salt, Cefoperazone,Sodium, Cefoperazone,T 1551
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
[Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders].
September 1991, The Japanese journal of antibiotics,
R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
[Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders].
August 1992, The Japanese journal of antibiotics,
R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
[Clinical experience with chemotherapy using sulbactam/cefoperazone for severe infections accompanying malignant hematological disorders].
June 1990, The Japanese journal of antibiotics,
R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
[Clinical evaluation of combination therapy with sulbactam/cefoperazone and amikacin sulfate for infections associated with hematological disorders].
October 1993, The Japanese journal of antibiotics,
R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
[A combined sulbactam/cefoperazone and amikacin therapy for the treatment of infections complicated with hematological diseases].
March 1993, The Japanese journal of antibiotics,
R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseases.
January 1989, Diagnostic microbiology and infectious disease,
R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
[Effect of combination therapy with sulbactam/cefoperazone and amikacin in the treatment of infectious diseases accompanied by hematological disorders].
August 1993, The Japanese journal of antibiotics,
R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
[Use of a combination of cefoperazone with sulbactam for treatment of patients with wound infections].
December 1994, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
[A combined consecutive therapy with fosfomycin and sulbactam/cefoperazone for bacterial infections associated with hematological diseases].
April 1995, The Japanese journal of antibiotics,
R Ohno, and T Hotta, and M Ogura, and K Ohnishi, and T Morishita, and T Murate, and M Okumura, and M Tanimoto, and C Inoue, and M Hamaguchi
The role of cefoperazone-sulbactam for treatment of severe melioidosis.
March 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!